MapLight Therapeutics, Inc. (MPLT) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$63.55M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$64.50M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$31.50M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$30.66M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$63.55M | (m) | (m) | (m) | $22.00K* | -$44.87M* | (m) | $53.44M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$64.50M | (m) | (m) | (m) | $24.00K | -$51.18M | (m) | $53.68M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$31.50M | (m) | (m) | (m) | $31.00K* | -$31.79M* | (m) | $27.09M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$30.66M | (m) | (m) | (m) | (m) | -$33.97M* | (m) | $26.85M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$23.54M | (m) | (m) | (m) | (m) | -$25.55M | (m) | $19.79M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$20.89M | (m) | (m) | (m) | (m) | (m) | (m) | $16.81M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$169.08M | (m) | (m) | (m) | $473.00K | -$138.14M | (m) | $138.35M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$82.95M | (m) | (m) | (m) | $770.00K | -$78.81M | (m) | $68.52M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |